Background: Ectopic pregnancy is a serious cause of maternal morbidity and mortality. Fallopian tube is the most common site. Ectopic pregnancy is often the consequence of chronic salpingitis. The aim of the study was to identify the various histopathological changes in the fallopian tube, which are removed following an ectopic tubal gestation. The prevalence of various risk factors in ectopic tubal pregnancy was also investigated. Methods: This descriptive study included 160 cases of ectopic tubal gestation received in the department during the study period. Slides were studied for various changes like chronic salpingitis, acute salpingitis, salpingitis isthmica nodosa, endometriosis, tuberculosis etc. Patient’s clinical details were obtained from the medical records.Results: The most frequent pathological finding was chronic salpingitis followed by salpingitis isthmica nodosa. It was noted that all cases with a positive history of pelvic inflammatory disease (PID), showed evidence of chronic salpingitis during histopathological examination. Chronic salpingitis was also noted in 45% cases who did not give a history of PID. Among the risk factors, a history of tubal sterilization was the most frequent one.Conclusions: Even though the mortality has reduced, ectopic pregnancy causes significant morbidity and affects the fertility of women. The rise in incidence could be due to increase in prevalence of sexually transmitted diseases, increase in tubal sterilization practices and frequent use of assisted reproduction technology. It is evident from the study that many cases of PIDs are left unidentified.
Background: The role of the pathologist reporting a case of post-chemotherapy carcinoma breast involves not just looking for residual carcinoma, but also classifying the patient into a response category, based on histological findings, and thus, analyzing the efficacy of treatment. Therapy related changes are well described in carcinoma breast. This study aims at classifying post-chemotherapy specimens based on response to chemotherapy according to the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 system and also identifying important associations between morphology, lymph node metastases and hormone receptor status with response.
Methods:The study classified thirty-one cases of carcinoma breast who had undergone neoadjuvant chemotherapy in our institution into three categories based on the NSABP B18 system, and analyzed the association of changes in morphology, hormone receptor status and metastases to lymph nodes with presence or absence of response.Results: The commonest response category was partial response (pPR) (17 cases), followed by pathological non-response (pNR) (11 cases) and pathological complete response (pCR) (3 cases). Statistically significant associations were found between presence of residual mass on gross assessment and presence of lymph node metastases with a poor response to treatment. Histopathological features and change in hormone receptor status did not show a significant association with response.
Conclusion:The majority of patients showed a partial response to therapy. Presence of a residual mass and presence of metastases to lymph nodes signified poor response.
Invasive micropapillary variant of mucinous carcinoma breast is an under-recognized category which shares features of both pure mucinous carcinoma and invasive micropapillary carcinoma. Due to its greater propensity for nodal metastasis and angioinvasion, the prognosis in this subtype is worser than pure mucinous carcinoma breast. Here we report a case of invasive micropapillary variant of mucinous carcinoma breast in a 43-year-old female.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.